HPV Vaccines

Human Papillomavirus (HPV) vaccine is an inactivated (not live) vaccine which protects against four major types of HPV.

These include two types that cause about 70% of cervical cancer and two types that cause about 90% of genital warts. HPV vaccine can prevent most genital warts and most cases of cervical cancer. Protection from HPV vaccine is expected to be long-lasting. But vaccinated women still need cervical cancer screening because the vaccine does not protect against all HPV types that cause cervical cancer.

Routine HPV Vaccination                                           

  • HPV vaccine is routinely recommended for girls 11 and 12 years of age
  • The HPV4 vaccine (the type recommended for prevention of genital warts in girls) may also be given in three doses to boys aged 9 to 26.

It is important for girls to get HPV vaccine before their first sexual contact -- because they have not been exposed to HPV.  For these girls, the vaccine can prevent almost 100% of disease caused by the four types of HPV targeted by the vaccine. However, if a girl or woman is already infected with a type of HPV, the vaccine will not prevent disease from that type. The vaccine is also recommended for girls and women 13 through 26 years of age who did not receive it when they were younger.

  • Advances in HPV Vaccine
  • HPV Vaccines for Men
  • HPV Vaccine risks and controversies
  • HPV Vaccine for Women

Related Conference of HPV Vaccines

July 27-28, 2018

31st Annual Congress on Vaccines, Clinical Trials & B2B

Vancouver, Canada
September 19-20, 2018

International Congress on Vaccines & Immunology

Amsterdam, Netherlands
October 22-23, 2018

30th World Congress on Vaccines and Immunization

Osaka, Japan
March 18-19, 2019

33rdAnnual Vaccines & Vaccination Congress

New York, USA

HPV Vaccines Conference Speakers

Recommended Sessions

Related Journals

Are you interested in